Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health filings document the disclosures of a public animal health company focused on products for farm animals and pets. The record includes Form 8-K reports on operating results, clinical or regulatory matters, capital-structure updates, credit-facility amendments, investor presentations, and restructuring-related exit or disposal activities.
Elanco's proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards, and governance practices. Its filings also provide formal disclosure around material events, financial reporting, and the capital arrangements that support the company's global animal health operations.
Elanco Animal Health officer Cabral Ramiro Martin reported a tax-withholding disposition of 6,492 shares of common stock at $24.88 per share on March 3, 2026. After this non-market transaction, he directly owned 283,874 common shares.
Elanco Animal Health Inc officer Jose Manuel Correia de Simas reported a tax-related share disposition. On March 3, 2026, he transferred 3,371 shares of common stock at $24.88 per share to cover tax withholding, and held 101,017 shares directly afterward.
Elanco Animal Health Inc executive Ellen de Brabander reported a tax-related stock transaction. On this Form 4, she disposed of 8,262 shares of Common Stock on March 3, 2026 through a tax-withholding disposition at a price of $24.88 per share, leaving her with 260,124 directly owned shares.
Elanco Animal Health Inc executive David S. Kinard reported a Form 4 transaction involving company common stock. On March 3, 2026, Kinard had a tax-related disposition of 3,433 shares of common stock at a reported price of $24.88 per share. This transaction is coded as a tax-withholding disposition, meaning shares were surrendered to cover tax obligations rather than being sold on the open market. After this transaction, Kinard directly held 214,264 shares of Elanco Animal Health Inc common stock.
Elanco Animal Health Inc executive Grace McArdle, EVP, Manufacturing and Quality, reported a tax-related share disposition. On March 3, 2026, she disposed of 4,322 shares of Elanco common stock at $24.88 per share in a transaction classified as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in an open-market trade. Following this transaction, she directly held 103,705 shares of Elanco common stock.
Elanco Animal Health Inc chief accounting officer James M. Meer reported a tax-related share disposition. On the reported date, he transferred 1,389 shares of Common Stock at $24.88 per share to cover tax withholding obligations, a non-open-market transaction. After this, he directly held 66,732 Common Stock shares.
Elanco Animal Health chief accounting officer James M. Meer reported equity compensation and related tax withholding transactions in company common stock. He received grants classified as restricted stock units covering 9,596 shares and 5,209 shares, both at a stated price of $0.00 per share. A separate transaction disposed of 4,787 shares at $26.40 per share to satisfy tax liability by delivering shares. The restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health executive Rajeev A. Modi reported multiple equity awards and related tax withholding transactions. On March 1, 2026, he received 29,025 employee stock options and 2,532 deferred stock units at no cost. He was also granted 41,690 shares of common stock and an additional 14,205 restricted stock units, all as equity awards.
The stock options and restricted stock units each vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The deferred stock units vest on December 31, 2027 and settle in stock or cash upon termination of employment under the Executive Deferral and Stock Match Plan. To cover tax obligations, 19,375 common shares were disposed of at $26.40 per share through share delivery. Following these transactions, Modi directly owned 160,293 shares of Elanco common stock as of March 1, 2026.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported several equity-award transactions dated March 1, 2026. He acquired an employee stock option covering 243,809 shares and deferred stock units covering 6,593 shares. He also received grants of 397,041 and 119,319 shares of common stock. The restricted stock units and options vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The deferred stock units vest on December 31, 2027 and settle upon termination of employment or under the Executive Deferral and Stock Match Plan. A separate transaction disposed of 229,982 shares of common stock at $26.40 per share for tax-withholding purposes, leaving 1,970,477 shares of common stock held directly, plus 167,000 shares held indirectly by a revocable trust and shares previously acquired under the employee stock purchase plan.
Elanco Animal Health executive Jose Manuel Correia de Simas reported multiple equity compensation movements. He received an employee stock option grant for 23,220 shares at an exercise price of $0.0000 per share and 937 deferred stock units, both recorded as derivative awards.
He also acquired 21,507 and 11,364 shares of common stock as restricted stock unit grants, while 9,883 shares of common stock were disposed of at $26.40 per share to cover taxes, a tax-withholding disposition rather than an open-market sale. Footnotes state the option and stock unit grants vest in thirds on March 1, 2027, March 1, 2028, and March 1, 2029, with certain deferred units vesting on December 31, 2027.